Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

“Our PD-1 inhibitor Libtayo is the standard of care in advanced ... from the Phase 3 C-POST trial evaluating the adjuvant use of the PD-1 inhibitor Libtayo in post-surgical high-risk cutaneous ...

It's been cleared for second-line use in patients who have progressed or are intolerant to hedgehog inhibitor therapy. Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out ...

Highlights from the ASCO presentations will include results from the Phase 3 C-POST trial, which explores the adjuvant use of PD-1 inhibitor Libtayo in high-risk cutaneous squamous cell carcinoma ...

Starting in 2025, the Eylea franchise as a whole began to decline due to competitive pressure from long-acting Vabysmo, which competes with Eylea HD, and Pabvlu, a biosimilar version of the original ...

Highlights from the ASCO presentations will include results from the Phase 3 C-POST trial, which explores the adjuvant use of PD-1 inhibitor Libtayo in high-risk cutaneous squamous cell carcinoma ...

Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q’25 - - Reported positive ...

Sensei is conducting a multi-center Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of solnerstotug as both a monotherapy and in ...

Regeneron continues to deliver growth on top/bottom line in the near to longer-term with Dupi and Libtayo, the analyst tells investors in a research note.

Britteny Mast is one of the few moms nowadays who wants her children to learn how to use a landline. Instagram / @momsfororegon Instead, for the times that she wants to leave them home alone ...

LONDON — New smartphones aren’t cheap and prices could reach even higher as globe trade tensions fueled by U.S. President Donald Trump’s tariff threats throw Asian exports into turmoil.